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The objective of this study is to assess the therapeutic importance of surgical castration, adjuvant hormonal treatment and
lymphadenectomy in endometrial stromal sarcoma (ESS). A retrospective and multicentric search was performed. Clinicopathologic
data were retrieved from cases that were confirmed to be ESS after central pathology review. The protocol was approved by the
Ethical Committee. ESS was confirmed histopathologically in 34 women, but follow-up data were available in only 31 women. Surgical
treatment (n¼31) included hysterectomy with or without bilateral salpingo-oophorectomy (BSO) in 23 out of 31 (74%) and 8 out
of 31 (26%) cases, respectively. Debulking surgery was performed in 6 out of 31 cases (19%). Stage distribution was as follows: 22
stage I, 4 stage III and 5 stage IV. Women with stage I disease recurred in 4 out of 22 (18%) cases. Among stage I women undergoing
hormonal treatment with or without BSO, 3 out of 15 (20%) and 1 out of 7 (14%) relapsed, respectively. Among stages III–IV
women receiving adjuvant hormonal treatment or not, 1 out of 5 (20%) and 3 out of 4 (75%) relapsed, respectively
(differences¼55.0%, 95% CI¼ 6.8–81.2%). Kaplan–Meier curves show comparable recurrence rates for stage I disease without
adjuvant hormonal treatment when compared to stages III–IV disease treated with surgery and adjuvant hormonal treatment.
Furthermore, women taking hormones at diagnosis have a better outcome when compared to women not taking hormonal
treatment. Three out of 31 (9%) patients had a systematic lymphadenectomy whereas 3 out of 31 (9%) had a lymph node sampling.
In one case, obvious nodal disease was encountered at presentation. Isolated retroperitoneal recurrence occurred in 1 out of 31 (3%)
of all cases and in 1 out of 8 (13%) recurrences. This single woman later also developed lung and abdominal metastases. Leaving
lymph nodes in situ does not appear to alter the clinical outcome of ESS. Although numbers are low, the retrospective data suggest
that the need for surgical castration (BSO) in premenopausal women with early-stage disease should be discussed with the patient on
an individual basis. The data support the current practice in some centres to administer adjuvant hormonal treatment.
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Endometrial stromal sarcomas (ESSs) are composed of cells that
resemble proliferative phase or hyperplastic endometrial stromal
cells (Hart and Yoonnessi, 1977; Evans, 1982). Currently, the
designation ESS is restricted to malignancies that were formally
referred to as low-grade stromal sarcomas (Evans, 1982; Oliva et al,
2000). Endometrial sarcomas without recognisable evidence of a
definite endometrial stromal phenotype, designated as poorly
differentiated endometrial sarcomas, are almost invariably high
grade (Evans, 1982; Oliva et al, 2000), and termed poorly
differentiated or undifferentiated uterine sarcomas. The classifica-
tion of a uterine sarcoma as ‘high-grade endometrial stromal
sarcoma’ should therefore be abandoned (Amant et al, 2004a).
Here, we focus on ESS, excluding endometrial stromal nodules and
undifferentiated or poorly differentiated uterine sarcomas.
The rarity of ESS, the historical mixture in studies with poorly
differentiated or undifferentiated uterine sarcomas and the recent
classification of ESS as a separate entity result in limited data on
‘keypoint’ issues, including standard treatment protocols.
Lymphatic invasion is well-established and pathognomonic for
ESS, formerly designated as endolymphatic stromal myosis.
Despite this, lymph node involvement is not considered a clinical
problem and pelvic lymphadenectomy is not added to hyster-
ectomy as the cornerstone of the treatment. However, recent data
suggested the incidence of lymph node metastases to be higher
than suspected (Riopel et al, 2005), suggesting the need for a more
extensive lymph node sampling (Riopel et al, 2005).
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sAlmost all ESSs show oestrogen and progesterone receptors
(Reich et al, 2000), rendering these tumours hormone sensitive.
Endometrial stromal sarcoma development and/or recurrences can
be induced by oestrogen-replacement therapy and tamoxifen (Beer
et al, 1995; Chu et al, 2003), whereas progestins (Gloor et al, 1982),
gonadotropin-releasing hormone analogues (Burke and Hickey,
2004) and aromatase inhibitors inhibit tumour growth (Maluf et al,
2001; Leunen et al, 2004). Recurrence rates in early-stage ESS are
high (Chang et al, 1990), and the impact of surgical castration and
adjuvant hormonal treatment needs to be investigated further.
Given the paucity of data on standard treatment modalities, we
aimed to explore the value of lymphadenectomy and surgical/
medicinal modification of hormonal levels.
MATERIALS AND METHODS
After approval of the study protocol by the Local Ethical
Committee, we retrospectively searched for ESS cases from 1986
to 2005, in a multicentric study with the following hospitals: UZ
Gasthuisberg Leuven, Institut Bordet Brussels, St Maria ziekenhuis
Halle, Stedelijk ziekenhuis Roeselare, AZ Groeninge Kortrijk, AZ St
Jan Genk, St Jozef ziekenhuis Malle, CHU Lie `ge, M Middelares
ziekenhuis St Niklaas. Representative slides were submitted for
central pathology review (PM).
The following information was retrieved through a search of
hospital charts: age, menopausal status, hormonal intake at
diagnosis, symptoms, delay in diagnosis, surgical treatment, stage,
adjuvant hormonal treatment, and recurrence and survival follow-
up information. Staging was retrospectively based on the surgical
and pathology reports and according to the endometrial cancer
FIGO staging (Amant et al, 2005). Postoperative progestin dosages
of minimum 200mgday
 1 were accepted as therapeutic, lower
dosages were considered as no adjuvant hormonal treatment. If the
patient recurred, the time from diagnosis until recurrence was
recorded. If the patient did not recur to date, the follow-up time
(from diagnosis until the end of follow-up for the patient) was
recorded. We are certain that the patient did not recur during this
period. Survival follow-up information was collected analogously,
with death rather than recurrence being the event of interest.
Statistical analysis
Due to the small sample size and general problems with
significance testing (Sterne and Davey Smith, 2001), we did not
use tests for statistical significance. Also, even though our study
has more data than other studies on this topic, the sample is too
small to draw firm conclusions. We can only investigate what our
data suggest and whether our results corroborate previous findings
or hypotheses.
When comparing proportions, we reported the difference in
proportions together with a 95% confidence interval (CI) on this
difference using method 10 from Newcombe (1998). Recurrence
data were used to generate Kaplan–Meier curves (Kaplan and
Meier, 1958) to visualise the estimated probability of recurrence at
different time points relative to the moment of surgery. Again, we
did not use any test (such as the Wilcoxon test) to test for
statistically significant differences between Kaplan–Meier curves.
All analyses were performed using SAS v9.1 (SAS Institute, Cary,
NC, USA).
RESULTS
We collected 34 women with ESS. One patient was excluded
because of concomitant breast cancer. Since one patient was lost to
follow-up and one patient also developed breast cancer during
follow-up, data on recurrence and survival were based on 31
women who had a hysterectomy and adequate follow-up data.
The median age at diagnosis was 44 years (range: 18–60 years).
Women were premenopausal in 25 out of 31 (81%) of cases. The
distribution of symptoms was as follows (more than one symptom
per patient possible): menstrual disorder (21, 68%), postmeno-
pausal bleeding (4, 13%), dyspareunia (4, 13%), abdominal mass
or pain (3, 10%), prolapsing polyp (1, 3%) and excessive
postpartum bleeding (1, 3%). Two patients (6%) were asympto-
matic and an enlarged uterus was found during yearly gynaeco-
logical preventive control. In one patient, diagnosis was based on
an accidental finding of a lung metastasis. Seven out of seven
women (100%) who received hormonal treatment at diagnosis had
stage I disease, while only 15 out of 24 (63%) women not receiving
hormones had stage I disease (difference¼37.5%, 95% CI¼ 1.5
to 57.3%). In 18 (60%) cases, an adequate pathologic diagnosis was
made shortly after the first presentation. For the purpose of data
analysis, an interval of more than 4 months was considered as a
delay, which occurred in 12 out of 30 (40%) cases. Data were not
available for one patient. The median delay between first symptom
and diagnosis was 20 months (range: 0–408 months). Women with
a correct diagnosis p4 months after the first presenting symptom
had stage I disease in 72% when compared to 75% when delay in
diagnosis exceeded 4 months (differences¼ 2.8, 95% CI¼ 30.9
to 29.3). When an arbitrarily cut-off value of 12 or 24 months was
used to define a delay, differences were 9.5% (95% CI¼ 20.6 to
43.4%) and 16.0% (95% CI¼ 18.3 to 55.0%; Table 1).
Surgical treatment included hysterectomy with or without BSO
in 23 out of 31 (74%) and 8 out of 31 (26%) cases, respectively.
Among operated women, 3 out of 31 (9%) had a thorough
lymphadenectomy (resection of 19, 31 and 33 nodes), whereas 3
out of 31 (9%) had a lymph node sampling (resection of 1, 2 and 3
nodes). In one case, which was diagnosed postpartum, obvious
nodal involvement was encountered. In fact, the external iliac
vessels and obturator space were involved with tumour that we
considered as nodal involvement. Debulking surgery was per-
formed in 6 out of 31 (19%). Stage distribution among all 31 cases
was as follows: 22 stage I, 4 stage III and 5 stage IV. Metastatic sites
were mainly pelvic and transperitoneal, whereas one patient
presented with lung metastasis.
Dosages from 10, 200, 500 and 1000mg medroxyprogesterone
acetate were used, whereas one patient used 10mg norethisterone
acetate. Adjuvant hormonal treatment, defined as a minimum of
200mg medroxyprogesterone acetate, was administered in 2 out of
22 (9%) and 5 out of 9 (56%) of cases with stages I and III–IV,
respectively. Two patients, both stage I, received adjuvant 10mg
medroxyprogesterone acetate or norethisterone acetate. One of
these patients recurred.
The mean length of follow-up for women with and without
recurrence was 62 months (median 46.5 months, range: 7–144)
and 64 months (median 56, range: 2–147), respectively. Actually,
23 out of 31 (74%) patients show no evidence of disease, 5 out of 31
Table 1 Comparison of clinical findings according to surgical stage
Stage I Stages III–IV
Hormonal treatment
a at diagnosis 7/22 (31.8) 0/9 (0)
Delay of diagnosis (months)
p4 13/18 (72) 5/18 (28)
44 9/12 (75) 3/12 (25)
p12 16/21 (76) 5/21 (24)
412 6/9 (67) 3/9 (33)
p24 19/25 (76) 6/25 (34)
424 3/5 (60) 2/5 (40)
Hysterectomy with BSO 15/22 (68) 8/9 (89)
Hormonal treatment after surgery 2/22 (9.1) 5/9 (56)
BSO¼bilateral salpingo-oophorectomy. Results are presented as n (%).
aOral
contraception or hormonal replacement.
Pelvic lymphadenectomy and bilateral salpingo-oophorectomy
F Amant et al
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s(16%) are dead of disease and 3 out of 31 (10%) are alive with
evidence of disease.
Among stage I women undergoing hormonal treatment with or
without BSO, 3 out of 15 (20%) and 1 out of 7 (14%) relapsed,
respectively (differences¼5.7%, 95% CI¼ 33.5 to 33.5%;
Table 2). Limiting the analysis to stage I premenopausal women
undergoing hysterectomy with or without BSO, relapse occurred in
3 out of 12 (25%) and 1 out of 6 (17%) women, respectively
(differences¼8.3%, 95% CI¼ 34.5 to 39.7%).
Women with hormonal treatment (oral contraceptives or
hormonal replacement) or not at diagnosis, recurred in 0 out of
7 (0%) and 8 out of 24 (33%) (differences¼33.3%, 95% CI¼ 53.3
to 5.3) and survived in 7 out of 7 (100%) and 19 out of 24 (79%)
(differences¼20.8%, 95% CI¼ 16.5 to 40.5) of cases, respectively
(Table 2). Since all seven women with hormonal treatment at
diagnosis were stage I, the positive effect of prediagnostic
hormonal intake appears to be stage related (Table 1).
Among stage I women receiving adjuvant hormonal treatment
or not, 0 out of 2 (0%) and 4 out of 20 (20%) relapsed, respectively
(differences¼ 20.0%, 95% CI¼ 46.8 to 41.6%). Among stages
III–IV women receiving adjuvant hormonal treatment or not, 1
out of 5 (20%) and 3 out of 4 (75%) relapsed, respectively
(differences¼ 55.0, 95% CI¼ 81.2 to 6.8). For stages III–IV
patients, survival was observed in 4 out of 5 (80%) and 2 out of 4
(50%; differences¼30.0%, 95% CI¼ 25.0 to 68.6%), respectively.
Altogether, 8 out of 31 (26%) patients experienced one or
multiple recurrences. Site of recurrence included abdominal (4 out
of 31; 13%), intraperitoneal pelvic (2 out of 31; 6%), vagina (1 out
of 31; 3%) or lungs (2 out of 31; 6%). A retroperitoneal recurrence
occurred in 1 out of 31 (3%) of all cases and in 1 out of 8 (12%) of
recurrences. However, this latter woman later also had recurrence
in lungs and intra-abdominally.
When comparing stage I ESS without adjuvant hormonal
treatment, women with or without BSO showed similar recurrence
rates as shown in the Kaplan–Meier curves (Figure 1). These
results suggest hormonal castration not to be beneficial for women
with early-stage ESS.
Kaplan–Meier curves showed lower recurrence and higher
survival numbers for women with stages III–IV ESS receiving
adjuvant hormonal treatment than for women with stages III–IV
ESS without adjuvant treatment (Figures 1 and 2). Women with
stage I ESS who did not receive adjuvant hormonal treatment had a
comparable recurrence rate when compared to stages III–IV
women having received adjuvant hormonal treatment. Recurrence
and survival data were worse among women with stage I ESS who
did not take hormones at diagnosis (data not shown), suggesting
that hormonal intake at diagnosis at least did not worsen the
outcome.
DISCUSSION
Although hysterectomy is the cornerstone in the treatment of ESS,
the need for a radical and complete surgical staging procedure is
clinically important but poorly studied. Although our results are
based on retrospective findings and are in small numbers, we
found no improved outcome for women with early-stage disease
undergoing surgical castration and pelvic lymphadenectomy.
These data suggest that the decision to perform an extended
surgical procedure should be discussed with the patient and taken
on an individual basis.
Table 2 Impact of the intake of hormonal treatment, addition of bilateral
salpingo-oophorectomy (BSO) and adjuvant hormonal treatment on
recurrence and survival
Recurrence Survival
Yes No Yes No
Hormonal treatment at diagnosis
Yes 0/0 (0) 7/7 (100) 7/7 (100) 0/0 (0)
No 8/24 (37) 16/24 (63) 19/24 (79) 5/23 (21)
BSO
No 2/8 (25) 6/8 (75) 7/8 (87) 1/8 (13)
Yes 6/23 (26) 17/23 (74) 19/23 (83) 4/23 (17)
Adjuvant hormonal treatment
Yes 1/7 (14) 6/7 (86) 6/7 (86) 1/7 (14)
No 7/24 (29) 17/24 (71) 20/24 (83) 4/24 (17)
Results are presented as n (%).
Condition: HT – no adjuvant – Stage I–II HT – no adjuvant – Stage III–IV
HT+BSO – no adjuvant – Stage I–II  HT+BSO – no adjuvant – Stage III–IV
HT+BSO – adjuvant – Stage I–II HT+BSO – adjuvant – Stage III–IV
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Figure 1 Kaplan–Meier plots show the estimated probability of recurrence in function of adjuvant hormonal treatment, type of surgery and stage.
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sIn the current practice, BSO is frequently added to the
hysterectomy given the hormone receptor positivity and given a
tendency towards recurrence even in early-stage disease. Especially
in young women, menopausal symptoms after surgical castration
importantly affect quality of life. Given the detrimental effect of
hormone replacement in two small series (Chu et al, 2003; Pink
et al, 2006), clinicians are reluctant to prescribe hormonal
treatment in women with a history of ESS and symptoms of
hormonal depletion. Therefore, the merits of concurrent surgical
castration need to be verified.
Although the results do not differ when postmenopausal women
were included (Table 2), stages I–II premenopausal women
undergoing hysterectomy with or without BSO relapsed in 3 out
of 12 (25%) and 1 out of 6 (17%), respectively. Numbers are too
small to make final conclusions, but BSO therefore does not seem
to improve the outcome. Comparing 12 premenopausal women
with ESS who did not undergo BSO with 24 matched controls, Li
et al (2005) observed similar progression-free survival and overall
survival in their series. Also Gadducci et al (1996) and Chu et al
(2003) observed comparable recurrence rates in women with and
without BSO. Thus, since current studies cannot demonstrate a
benefit for women undergoing hormonal castration for a
hormone-sensitive disease and given the side effects of hormonal
castration, it appears advisable to leave the ovaries in situ when
ESS is diagnosed. Especially in young premenopausal women, this
message is of clinical importance.
Kaplan–Meier plots illustrate the impact of type of surgery
(hysterectomy with or without BSO) and adjuvant hormonal
treatment for early- and advanced-stage disease (Figures 1 and 2).
From this analysis, it appears that women with advanced-stage
disease benefit from adjuvant hormonal treatment. Although this
message seems obvious, this was not reported before. Only two
women with early-stage ESS took adjuvant hormones. Surpris-
ingly, women with early-stage disease not receiving adjuvant
hormonal treatment had a comparable recurrence rate when
compared to women with stages III–IV disease with adjuvant
hormonal treatment. The observation that for recurrent disease,
adjuvant hormonal treatment can compensate for stage is
remarkable. These observations underscore the hormonal sensi-
tivity of ESS. Given the considerable recurrence rates, these results
suggest adjuvant hormonal treatment to be beneficial in early- and
advanced-stage ESS. This hypothesis is in line with the observation
that 6 out of 8 (75%) and 2 out of 7 (29%) recurrences were noted
in early-stage women with and without adjuvant hormonal
treatment, respectively (Chu et al, 2003). Given the paucity of
retrospective data and the difficulties in organising prospective
trials in ESS, the importance of adjuvant hormonal intake is
clinically relevant.
The apparent paradox between the absence of a benefit of
hormonal castration and clinical benefit of adjuvant progestins can
probably be explained by a dosage effect. Daily dosages of 160mg
megestrolacetate (Chu et al, 2003) or 250mg medroxyprogester-
oneacetate are considered high dose, whereas physiologic effects of
both drugs are already obtained with 5mg dosages.
We challenged the role of lymphadenectomy in primary surgery.
Recently, Riopel et al (2005), reported 5 out of 15 patients to have
involved nodes somewhere in the course of their disease. Looking
into detail in these data, 4 out of 5 cases with positive nodes
occurred in women with primary advanced-stage (n¼2) or
recurrent disease (n¼2). Reich et al (2005) reported on two cases
with recurrent disease in the lymphatic system. These data suggest
a higher than expected percentage of nodal involvement in
advanced or recurrent ESS that might necessitate retroperitoneal
exploration in this subgroup.
Data in early-stage disease are however different. Riopel et al
(2005) mention only one case with disease otherwise limited to the
uterus and positive nodes. Worthy of note, there was an interval of
3 months between hysterectomy and the second surgery during
which the positive node was found. Interestingly, the case with
nodal involvement at presentation from the current series was
diagnosed after a postpartum haemorrhage and, in this case, nodal
involvement at the obturator level was diagnosed 4 weeks after
delivery (Leunen et al, 2003). It is intriguing to hypothesise that
uterine manipulation (Riopel et al, 2005) or activity (Leunen et al,
2003) might contribute to nodal involvement in ESS otherwise
limited to the uterus.
In the current study, a thorough lymphadenectomy or lymph
node sampling was performed in a minority of cases only (three
and three patients, respectively). Only in the case diagnosed
shortly after delivery, nodal involvement was noted (Leunen et al,
2003). With regard to recurrence in the lymphatic system, only 1
out of 31 (3%) patient in this study developed a retroperitoneal
pelvic recurrence. However, this patient subsequently developed
lung- and intra-abdominal metastases. The low retroperitoneal
Condition: HT – no adjuvant – Stage I–II HT – no adjuvant – Stage III–IV
HT+BSO – no adjuvant – Stage I–II  HT+BSO – no adjuvant – Stage III–IV
HT+BSO – adjuvant – Stage I–II HT+BSO – adjuvant – Stage III–IV
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Figure 2 Kaplan–Meier plots show the estimated probability of survival in function of type of adjuvant hormonal treatment, type of surgery and stage.
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srecurrence rate (3%) in our study and the tendency of ESS to recur
at different sites (Chang et al, 1990) suggest systematic lympha-
denectomy to bear little clinical benefit in early-stage ESS.
Tumours arising in young women reduce the serendipity
(oncological mindset) of the pathologist, and this adds to the
diagnostic problem and delay in diagnosis (Amant et al, 2003).
Surprisingly, in this series, however, delay in diagnosis did not
alter stage distribution (stages I vs III–IV; Table 1). Also
surprisingly, when a definition of 12 and 24 months was used to
define a delay, stage differences were small (Table 2). Probably, the
absence of impact of delay in diagnosis on stage distribution is
explained by the indolent nature of disease (significant numbers of
ESS present with early-stage disease, even when delay in diagnosis
exceeds 24 months; Table 1) and the tendency for transperitoneal
spread (asymptomatic spread results in considerable advanced-
stage ESS at presentation; Table 1).
Also in the survival analysis, a relative good outcome is noted
for stages III–IV ESS (Figure 2). Given the hormone sensitivity
and the indolent nature of ESS, we consider ESS as a chronic
disorder for which we apply repetitive surgery. We perform
secondary and tertiary debulking surgery with organ resection and
thoracotomies to tackle recurrent disease. Progestins (Gloor et al,
1982), gonadotropin-releasing agonists (Burke and Hickey, 2004)
and aromatase inhibitors (Maluf et al, 2001; Leunen et al, 2004) are
prescribed as systemic treatment in between the surgeries.
Probably, some extrapolations can be made to uterine
adenosarcoma. Uterine adenosarcoma was first described by
Clement and Scully in 1974 (Clement and Scully, 1974). These
rare neoplasms have a benign epithelial component, whereas the
stromal component typically is of low grade. In 56% of the cases,
the sarcomatous component was ESS alone and in an additional
9% of cases a mixture of ESS and fibrosarcoma was present
(Clement and Scully, 1990). In uterine adenosarcoma lacking
sarcomatous overgrowth, we documented that in 18 out of 20
(90%) of the cases either the oestrogen or the progesterone
receptor stained positive in the sarcomatous component (Amant
et al, 2004b). Given a histological and biological similarity, we
propose to extrapolate the results in ESS to uterine adenosarcoma
without sarcomatous overgrowth.
CONCLUSIONS
Endometrial stromal sarcoma is an indolent uterine tumour for
which primary surgery including hysterectomy with BSO is
regarded the standard primary treatment. However, in our
retrospective case series, BSO did not reduce recurrence rate in
premenopausal stage I women. These data suggest that ovarian
preservation in young women with low-stage ESS should be
discussed on an individual basis with the patient. Our data also
suggest that pelvic lymphadenectomy bears little clinical benefit.
Our data show high-recurrence rates in early-stage ESS, supporting
the current practice in some centres to administer adjuvant
hormonal treatment.
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